584 related articles for article (PubMed ID: 27267134)
21. Safety of topical calcineurin inhibitors for the treatment of atopic dermatitis.
Munzenberger PJ; Montejo JM
Pharmacotherapy; 2007 Jul; 27(7):1020-8. PubMed ID: 17594208
[TBL] [Abstract][Full Text] [Related]
22. Systematic review and meta-analysis of randomized clinical trials (RCTs) comparing topical calcineurin inhibitors with topical corticosteroids for atopic dermatitis: A 15-year experience.
Broeders JA; Ahmed Ali U; Fischer G
J Am Acad Dermatol; 2016 Aug; 75(2):410-419.e3. PubMed ID: 27177441
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: systematic review and meta-analysis of randomized controlled trials.
Schmitt J; von Kobyletzki L; Svensson A; Apfelbacher C
Br J Dermatol; 2011 Feb; 164(2):415-28. PubMed ID: 20819086
[TBL] [Abstract][Full Text] [Related]
24. Topical calcineurin inhibitors in pediatric atopic dermatitis: a critical analysis of current issues.
Orlow SJ
Paediatr Drugs; 2007; 9(5):289-99. PubMed ID: 17927301
[TBL] [Abstract][Full Text] [Related]
25. What Is the Risk of Harm Associated With Topical Calcineurin Inhibitors?
Hanna S; Zip C; Shear NH
J Cutan Med Surg; 2019; 23(4_suppl):19S-26S. PubMed ID: 31476938
[TBL] [Abstract][Full Text] [Related]
26. Pimecrolimus in atopic dermatitis: consensus on safety and the need to allow use in infants.
Luger T; Boguniewicz M; Carr W; Cork M; Deleuran M; Eichenfield L; Eigenmann P; Fölster-Holst R; Gelmetti C; Gollnick H; Hamelmann E; Hebert AA; Muraro A; Oranje AP; Paller AS; Paul C; Puig L; Ring J; Siegfried E; Spergel JM; Stingl G; Taieb A; Torrelo A; Werfel T; Wahn U
Pediatr Allergy Immunol; 2015 Jun; 26(4):306-15. PubMed ID: 25557211
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children.
Wahn U; Bos JD; Goodfield M; Caputo R; Papp K; Manjra A; Dobozy A; Paul C; Molloy S; Hultsch T; Graeber M; Cherill R; de Prost Y;
Pediatrics; 2002 Jul; 110(1 Pt 1):e2. PubMed ID: 12093983
[TBL] [Abstract][Full Text] [Related]
28. Topical corticosteroids and topical calcineurin inhibitors in the treatment of atopic dermatitis: focus on percutaneous absorption.
Pariser D
Am J Ther; 2009; 16(3):264-73. PubMed ID: 19262357
[TBL] [Abstract][Full Text] [Related]
29. Topical treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials.
Chu DK; Chu AWL; Rayner DG; Guyatt GH; Yepes-Nuñez JJ; Gomez-Escobar L; Pérez-Herrera LC; Díaz Martinez JP; Brignardello-Petersen R; Sadeghirad B; Wong MM; Ceccacci R; Zhao IX; Basmaji J; MacDonald M; Chu X; Islam N; Gao Y; Izcovich A; Asiniwasis RN; Boguniewicz M; De Benedetto A; Capozza K; Chen L; Ellison K; Frazier WT; Greenhawt M; Huynh J; LeBovidge J; Lio PA; Martin SA; O'Brien M; Ong PY; Silverberg JI; Spergel JM; Smith Begolka W; Wang J; Wheeler KE; Gardner DD; Schneider L
J Allergy Clin Immunol; 2023 Dec; 152(6):1493-1519. PubMed ID: 37678572
[TBL] [Abstract][Full Text] [Related]
30. How Clinically Relevant Are Treatment Comparisons of Topical Calcineurin Inhibitor Trials for Atopic Eczema?
Wilkes SR; Nankervis H; Tavernier E; Maruani A; Williams HC
J Invest Dermatol; 2016 Oct; 136(10):1944-1949. PubMed ID: 27265005
[TBL] [Abstract][Full Text] [Related]
31. Safety of topical corticosteroids in atopic eczema: an umbrella review.
Axon E; Chalmers JR; Santer M; Ridd MJ; Lawton S; Langan SM; Grindlay DJC; Muller I; Roberts A; Ahmed A; Williams HC; Thomas KS
BMJ Open; 2021 Jul; 11(7):e046476. PubMed ID: 34233978
[TBL] [Abstract][Full Text] [Related]
32. A 5-year randomized trial on the safety and efficacy of pimecrolimus in atopic dermatitis: a critical appraisal.
Weidinger S; Baurecht H; Schmitt J
Br J Dermatol; 2017 Oct; 177(4):999-1003. PubMed ID: 28868633
[TBL] [Abstract][Full Text] [Related]
33. Spotlight on topical pimecrolimus in pediatric atopic dermatitis.
Yang LP; Curran MP
Am J Clin Dermatol; 2010; 11(4):295-8. PubMed ID: 20509720
[TBL] [Abstract][Full Text] [Related]
34. Pimecrolimus: a review of its use in atopic dermatitis.
Wellington K; Noble S
Am J Clin Dermatol; 2004; 5(6):479-95. PubMed ID: 15663345
[TBL] [Abstract][Full Text] [Related]
35. Comparative effectiveness of topical calcineurin inhibitors in adult patients with atopic dermatitis.
Frankel HC; Qureshi AA
Am J Clin Dermatol; 2012 Apr; 13(2):113-23. PubMed ID: 22263704
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials.
Ashcroft DM; Dimmock P; Garside R; Stein K; Williams HC
BMJ; 2005 Mar; 330(7490):516. PubMed ID: 15731121
[TBL] [Abstract][Full Text] [Related]
37. Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results.
Silverberg JI; de Bruin-Weller M; Bieber T; Soong W; Kabashima K; Costanzo A; Rosmarin D; Lynde C; Liu J; Gamelli A; Zeng J; Ladizinski B; Chu AD; Reich K
J Allergy Clin Immunol; 2022 Mar; 149(3):977-987.e14. PubMed ID: 34403658
[TBL] [Abstract][Full Text] [Related]
38. A safety assessment of topical calcineurin inhibitors in the treatment of atopic dermatitis.
Lebwohl M; Gower T
MedGenMed; 2006 Oct; 8(4):8. PubMed ID: 17415290
[TBL] [Abstract][Full Text] [Related]
39. Association Between Topical Calcineurin Inhibitor Use and Keratinocyte Carcinoma Risk Among Adults With Atopic Dermatitis.
Asgari MM; Tsai AL; Avalos L; Sokil M; Quesenberry CP
JAMA Dermatol; 2020 Oct; 156(10):1066-1073. PubMed ID: 32785626
[TBL] [Abstract][Full Text] [Related]
40. Cancer risk with topical calcineurin inhibitors, pimecrolimus and tacrolimus, for atopic dermatitis: a systematic review and meta-analysis.
Devasenapathy N; Chu A; Wong M; Srivastava A; Ceccacci R; Lin C; MacDonald M; Wen A; Steen J; Levine M; Pyne L; Schneider L; Chu DK;
Lancet Child Adolesc Health; 2023 Jan; 7(1):13-25. PubMed ID: 36370744
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
